Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to move ahead follows talks with FDA suggesting existing data are sufficient for filing, despite failure of one of two pivotal trials.